Brind.
  1. The FDA granted clearance for a nerve ablation system from NeuroOne Medical Technologies, which has a distribution agreement with Zimmer Biomet.

FDA cleared NeuroOne Medical Technologies' OneRF system for facial pain treatment.

2 reports, 2 independent Updated Aug 19
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

FDA cleared NeuroOne Medical Technologies' OneRF system for facial pain treatment.

Who's involved

What this event is mainly about
FDA

How it developed

Newest first. Tap a step to see who reported it.
  1. NeuroOne Medical Technologies filed a submission and received a patent allowance for its OneRF Trigeminal Nerve Ablation System.Sub-event
  2. FDA approved NeuroOne's OneRF system for facial pain treatment.1 source

Keep exploring

Part of

The FDA granted clearance for a nerve ablation system from NeuroOne Medical Technologies, which has a distribution agreement with Zimmer Biomet. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksNMTC Stock Gains as FDA Clears OneRF System for Facial Pain Treatment NeuroOne Medical Technologies Corporation NMTC recently received FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation Sys
  • GlobeNewswireNeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical